Nanjing Simcere-Medgenn Bio-Pharmaceuticals

Nanjing Simcere-Medgenn Bio-Pharmaceuticals is a specialized biotechnology subsidiary of Simcere Pharmaceutical Group, primarily focused on the development and commercialization of innovative anti-angiogenic therapies for oncology. The company is best known for its flagship product, Endostar (recombinant human endostatin), which was the first of its kind to be approved in China for the treatment of non-small cell lung cancer. Simcere-Medgenn operates as a key research and manufacturing hub within the Simcere ecosystem, leveraging advanced recombinant protein technology. Its business encompasses the full lifecycle of drug development, from early-stage R&D to large-scale GMP manufacturing and clinical application. The company continues to explore expanded indications for its existing portfolio while supporting Simcere's broader pipeline in oncology and infectious diseases.